PASG Stock Summary and Trading Ideas (Passage Bio | NASDAQ:PASG)

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Passage Bio trades on the NASDAQ stock market under the symbol PASG.

As of December 15, 2025, PASG stock price climbed to $10.05 with 81,989 million shares trading.

PASG has a beta of 1.66, meaning it tends to be more sensitive to market movements. PASG has a correlation of 0.07 to the broad based SPY ETF.

PASG has a market cap of $31.95 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PASG traded as high as $38.40 and as low as $5.12.

The top ETF exchange traded funds that PASG belongs to (by Net Assets): VTI, VXF, DFAC.

PASG has underperformed the market in the last year with a return of -35.8%, while SPY returned +13.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PASG shares. However, PASG has outperformed the market in the last 3 month and 2 week periods, returning +43.6% and +13.8%, while SPY returned +3.8% and -0.4%, respectively. This indicates PASG has been having a stronger performance recently.

PASG support price is $9.07 and resistance is $10.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PASG shares will trade within this expected range on the day.